Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior PLC's Chief Scientific Officer, Christian Heidbreder, reports his current equity holdings in the company. Heidbreder beneficially owns 157,140 ordinary shares on a direct basis.
He also holds 82,287 restricted stock units, each representing a contingent right to receive one ordinary share of Indivior PLC. These RSUs were granted on March 7, 2025 and vest in a single installment on March 7, 2028.
Indivior PLC reported the initial holdings of its Chief Legal Officer, Jeffrey W. Burris, in a Form 3 insider filing. He directly beneficially owns 760 ordinary shares of Indivior PLC. He also holds 71,743 restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. These RSUs were granted on March 7, 2025 and are scheduled to vest in a single installment on March 7, 2028, aligning his long-term compensation with the company’s future performance.
Indivior PLC executive Barry Patrick A, Chief Commercial Officer, filed an initial ownership report showing beneficial ownership of 130,312 restricted stock units. Each RSU represents a contingent right to receive one ordinary share of Indivior PLC. The RSUs were granted on June 2, 2025 and are scheduled to vest in a single installment on June 2, 2028, subject to applicable conditions. The filing is a Form 3, reflecting his derivative equity holdings as of the January 1, 2026 event date and does not report any purchase or sale transaction.
Indivior PLC’s Chief Accounting Officer, Anderson Woodrow D, has reported his initial beneficial ownership of the company’s securities as of 01/01/2026. He directly holds 4,390 ordinary shares.
He also holds several batches of restricted stock units (RSUs), each representing a right to receive one ordinary share of Indivior PLC. These include 5,946 RSUs granted on March 3, 2023 that vest in a single installment on March 3, 2026, 5,093 RSUs granted on March 8, 2024 that vest on March 8, 2027, and 29,478 RSUs granted on March 7, 2025 that vest on March 7, 2028. All positions are reported as directly owned.
Indivior PLC reported changes to executive compensation. On December 12, 2025, the Board of Directors approved base salary increases for two executive officers, effective January 1, 2026. The Chief Executive Officer, Joseph Ciaffoni, will have his annual base salary increased from $1,050,000 to $1,115,000. The Chief Financial Officer, Ryan Preblick, will have his annual base salary increased from $559,000 to $604,000. The Board made these changes after reviewing competitive market data and considering recommendations from the Compensation Committee and its compensation consultant.
Indivior PLC obtained strong shareholder approval for a scheme of arrangement and amended and restated articles of association that reshape its corporate structure. A new Article 136 ensures that any ordinary shares issued after the Amended Articles take effect but before the Scheme Record Time are automatically subject to the scheme, so all Indivior PLC shareholders will become shareholders of Indivior Pharmaceuticals, Inc. and Indivior PLC will become its wholly-owned subsidiary.
At a Court Meeting, 15 shareholders voted for the scheme and 2 against, with 94,968,161 votes for and 46,544 against, exceeding the English law requirement of a majority in number representing not less than seventy-five percent in value of shares present and voting. At an Extraordinary General Meeting, shareholders passed six related special resolutions, including authorising directors to implement the scheme, reducing share capital, issuing New Indivior Shares, amending articles, re-registering the company as a private company limited by shares, and adopting post-scheme articles. Completion of the scheme still depends on sanction by the High Court of Justice, with a hearing expected on January 22, 2026, and completion is expected later in January 2026.
Indivior PLC reported that it has fulfilled all remaining obligations under its Resolution Agreement with the U.S. Department of Justice and the U.S. Attorney’s Office for the Western District of Virginia. After these obligations were satisfied, the Resolution Agreement terminated on November 20, 2025. The company also issued a press release on the same date announcing payment of the remaining amounts owed to the DOJ, which is included as an exhibit to this report. This marks the formal conclusion of that material agreement with U.S. authorities.
Indivior PLC announced it has mailed and published a scheme circular for an Extraordinary General Meeting on December 11, 2025. Shareholders will vote on the proposed re‑domestication of the company from the U.K. to Delaware. The scheme circular is furnished as Exhibit 99.1.
Indivior PLC announced an enterprise-wide restructuring under its Indivior Action Agenda to simplify operations and focus on growth drivers. The company expects to realize at least $150 million in annual operating expense savings beginning in 2026 and to enter Phase II — Accelerate — with immediate accretion to the bottom line starting January 2026.
Actions include headcount reductions, R&D facility closures, discontinuing sales and marketing support for OPVEE, and optimizing the Rest of World footprint by exiting several non-U.S. markets while retaining Canada, Australia, France and sales in Germany, which represent 77% of forecasted ROW net revenue and 94% of forecasted ROW adjusted EBITDA. Indivior expects total pre-tax restructuring charges of approximately $105 to $130 million, including $73 to $92 million of cash costs. In Q3 2025, $65 million was recognized and adjusted from non-GAAP results. Itemized estimates include severance of $33 to $37 million, real estate of $15 to $21 million, asset impairments of $21 to $27 million, contract terminations of $25 to $28 million, and $11 to $17 million for consulting, legal, and tax planning.
Indivior PLC filed its Q3 2025 10-Q, reporting net revenue of $314 million (up from $307 million) and net income of $42 million (vs. $22 million). Diluted EPS was $0.33 (vs. $0.16). Gross margin was 73% (vs. 79%), reflecting Q3 charges tied to portfolio actions.
SUBLOCADE remained the growth driver with total net revenue of $219 million (U.S. $203 million), offsetting declines in sublingual products, OPVEE, and PERSERIS. For the first nine months, net revenue was $881 million (vs. $889 million) with net income of $108 million (vs. a $14 million loss).
The company recorded $72 million in Q3 costs, including $35 million for Phase 1 of the Indivior Action Agenda and $37 million related to discontinuing sales and marketing support for OPVEE. Cash and equivalents were $445 million and debt totaled $322 million (current $18 million, long‑term $304 million). Operating cash flow for the first nine months was $194 million. The company plans to exit several non‑U.S. markets, with expected charges of $30–$50 million, primarily in Q4 2025 and Q1 2026. Accrued litigation settlement expenses were $406 million, including an opioid-related settlement accrual of $80 million.